Further research found that by combining GAS5 with CEA, the AUC of the combined group is 0.929, indicating that GAS5 combined with CEA can improve the positive rate of diagnosis in NSCLC patients (Li et al., 2019). This evidence concerns the gene GAS5 and non-small cell lung carcinoma.